Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Joaquin Duato

Johnson & Johnson Earnings Top Forecasts On Solid Medical Device Sales

“We are entering the back half of the year from a position of strength with numerous catalysts, including becoming a two-sector company focused on Pharmaceutical and MedTech innovation," said CEO Joaquin Duato.

Johnson & Johnson Tops Q1 Earnings Forecast On Consumer Unit Gains, Boosts Dividend

Johnson & Johnson Tops Q1 Earnings Forecast On Consumer Unit Gains, Boosts Dividend

“Our first quarter results demonstrate strong performance across all three segments of our business," said CEO Joaquin Duato.

The Strongest Pharma Stock This Week

The Strongest Pharma Stock This Week

Tighter bank lending and the Fed’s continued fight against inflation will likely push the economy into a recession this year. In this scenario, investors can look to invest in the pharma giant Johnson & Johnson (JNJ), given its financial strength, reliable dividend payments, and solid growth prospects. Read more….

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

1 Stock to Buy for Safety in This Volatile Market

With the Fed anticipating higher interest rate hikes than previously expected, the stock market is expected to remain volatile in the upcoming months. Given its strong balance sheet, brand recognition, and solid dividend payouts, it could be safe to invest in Johnson & Johnson (JNJ). Read more….

1 Dividend Stock to Buy Now and Retire on Later

Johnson & Johnson (JNJ) continued its business momentum in the third quarter of fiscal 2022, driven by steady demand for its products and innovative, advancing portfolio and pipeline. Moreover, the company has a record of raising its dividend for 60 consecutive years. Amid the current uncertain market conditions, this fundamentally…

1 Stock That's Always a Safe Bet Amid Market Volatility

Leading healthcare company Johnson & Johnson (JNJ) has been able to navigate the volatile market conditions due to the defensive nature of its business and solid fundamentals. Moreover, the company has an impressive history of increasing its dividends. Given JNJ’s robust financials, high profitability, and consistent dividend payouts, we think…

Abiomed Stock Soars After $16.6 Billion Johnson & Johnson Takeover Amid Deeper Medical Devices Push

"The addition of Abiomed is an important step in our vision for the new Johnson & Johnson focused on Pharmaceutical and MedTech," said CEO Joaquin Duato.

inkl

Read news from The Economist, FT, and more,
with one subscription

Johnson & Johnson Tops Q3 Earnings Forecast, Boosts 2022 Outlook On Pharma Strength

Johnson & Johnson Tops Q3 Earnings Forecast, Boosts 2022 Outlook On Pharma Strength

“Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,” said CEO Joaquin Duato.

Johnson & Johnson Stock Gains After Unveiling $5 Billion Buyback Program, Repeating Profit Targets

Johnson & Johnson Stock Gains After Unveiling $5 Billion Buyback Program, Repeating Profit Targets

"We have the ability to invest in innovation, grow our dividend, execute strategic acquisitions, and take this action to deliver shareholder returns," said CEO Joaquin Duato.

Johnson & Johnson Tops Q2 Earnings Forecast, Trims 2022 Outlook On Strong Dollar Impact

Johnson & Johnson Tops Q2 Earnings Forecast, Trims 2022 Outlook On Strong Dollar Impact

"Our solid second quarter results across Johnson & Johnson reflect the strength and resilience of our company’s market leadership in the midst of macroeconomic challenges,” said CEO Joaquin Duato.

1

People

Dipanjan BanchurSince

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Johnson & Johnson (

Medical – Pharmaceuticals

Johnson Johnson JNJ

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

160,938 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play